Pharmacology. In the article "Lipocortin 1 mediates dexamethasone-induced growth arrest of the A459 lung adenocarcinoma cell line" by J. D. Croxtall and R. J. Flower, which appeared in number 8, April 15, 1992, of Proc. Natl. Acad. Sci. USA (89,(3571)(3572)(3573)(3574)(3575) 
steroidal antiinflammatory drugs indomethacin (1 jtM) and naproxen (10 ,uM) and human recombinant lipocortin 1 (0.05-5.0 #g/ml) also produce growth arrest in this cell line. During proliferation A549 cells spontaneously release prostaglandin E2 [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] ng (28-57 pmol) per ml per 5-day period] into the growth medium. In concentrations that cause growth-arrest, dexamethasone, indomethacin, and lipocortin 1 abolish the generation of this eicosanoid by A549 cells. Prostaglandin E2 itself (0.01-1 pM) stimulates cell growth and partially reverses (=50%) the inhibition of growth caused by dexamethasone and indomethacin. Addition of the neutralizing anti-lipocortin 1 monoclonal antibody 1A (5 ,ug/ml), but not the nonneutralizing anti-lipocortin monoclonal antibody 1B, substantially reversed (>80%) the inhibitory activity of dexamethasone on both growth and prostaglandin E2 synthesis. The generation of prostaglandin E2 by A549 cells seems to be an important regulator of cell proliferation in vitro and the dexamethasoneinduced suppression of proliferation in this model is attributable to eicosanoid inhibition caused by lipocortin 1.
Glucocorticoids inhibit the proliferation of many cell types including thymocytes (1) , lymphocytes (2, 3) , fibroblasts (4), muscle (5) , skin (6) , leukemic cell lines (7, 8) , and hepatoma cells (9) in culture. The molecular mechanisms involved in cell growth control have not been clarified although several studies implicate eicosanoids as modulators of this aspect of cell physiology (e.g., ref. 10 ). The biological actions of glucocorticoids in many cells are brought about by discrete changes in gene expression and protein synthesis (11, 12) after combination with specific intracellular receptors. Several, but apparently not all, cell types respond to glucocorticoids with increased intracellular or pericellular amounts of an eicosanoid-suppressive factor now identified as chiefly lipocortin 1 (also known as annexin 1; for review, see ref. 13 ). This protein, which is a member of a superfamily of proteins characterized by their ability to bind calcium and anionic phospholipids (14) , has a variety of biological actions. For example, systemic administration or extracellular application of the protein inhibits eicosanoid generation (15) , cytokineand poly(I)-poly(C)-induced fever (16, 17) , acute inflammatory oedema (18) , neutrophil migration (19) , and ischemic damage to the brain (20) and causes differentiation of squamous carcinoma cells (21) . In addition, lipocortins may play a role in several other cellular processes including exocytosis (22) , chemotaxis (19) , anticoagulation (23), growth-factor signal transduction (24, 25) , cellular differentiation (26) , and cell growth (27) .
We now report that the synthetic glucocorticoid dexamethasone potently inhibits the growth of A549 cells in vitro and that suppression of prostaglandin (PG) E2 formation brought about by a steroid-induced increase in pericellular lipocortin 1 seems to be a major mechanism controlling this response. Treatmnent, h medium without steroid were still growth-arrested compared to control cells after 3 days of culture ( Fig. 1 Inset). At 10 nM, dexamethasone significantly (P < 0.001) inhibited A549 cell proliferation after 8 and 12 days of treatment ( Fig. 2 ). This effect was prevented by 1 gM RU38486 at days 8 and 12 and by 1 ILM RU43044 at day 12. The antiglucocorticoids themselves (1 FmM) have no significant effect on A549 cell proliferation. These data are congruent with the hypothesis that the effect of dexamethasone is mediated through the glucocorticoid receptor and additional evidence for this is the fact that progesterone (1 t&M) or aldosterone (1 AM, data not shown) produces no significant inhibition of cell growth whereas hydrocortisone (1 ,uM), another glucocorticoid, produces a qualitatively similar effect to dexamethasone (35 ± 5.4% inhibition; P < 0.001; n = 2 experiments). Cells displayed no morphological evidence of injury even after exposure to the highest concentration of dexamethasone used (1 1LM) for 4 days and were >99% viable at this time according to the trypan blue exclusion test.
MATERIALS
In addition to the steroids, indomethacin, in a concentration that completely inhibits the cyclooxygenase enzyme (1 iLM) caused 98 ± 8.3% inhibition of cell growth and naproxen (10 AM) reduced cell replication to 53.7 ± 6.2% of the control values.
Increases in Cell Surface Lipocortin 1 Induced by Glucocorticoids. In addition to decreasing cellular proliferation, dexamethasone treatment concomitantly increased, in a time-dependent manner, the amount oflipocortin 1 that could be removed from the extracellular cell surface by washing with EDTA. Fig. 3A shows that the amount of lipocortin 1 recovered from the cell surface was maximal 2-6 h after dexamethasone treatment and returned to basal levels (within 24 h). Progesterone and aldosterone (1 uM) had no effect on lipocortin 1 expression at any time point (data not shown). synthesis of the protein or by translocation of preexisting intracellular protein to the pericellular domain. Extracellular lipocortin 1 always appeared as a doublet with molecular masses of 37 and 33 kDa. The former is undoubtedly the native species whereas the latter is a commonly encountered N-terminal cleavage product.
The induction by dexamethasone of lipocortin 1 on the cell surface was inhibited (51%) by an equimolar concentration (1 ,uM) of RU38486 but an equimolar amount of RU43044, which has a lower affinity for the glucocorticoid receptor, was ineffective. However, when A549 cells were maintained in medium containing lower concentrations of dexamethasone (1 nM), RU38486 or RU43044 (1 AtM) substantially reduced (90% and 80%, respectively) the appearance of lipocortin 1 at the cell surface (Fig. 3B) .
Effect of Recombinant Human Lipocortin 1 on A549 Cell Proliferation. In three experiments, exogenous human recombinant lipocortin 1 was added to A549 cell cultures and proliferation was assessed after 3 days. Fig. 4 shows one such experiment in which a dose-related inhibition of cell proliferation by lipocortin 1 was observed with significant effects being detectable at 0.05 gg/ml (1.4 nM). In this particular experiment the original cell number was 5 x 104, which tripled during the 4-day culture. Maximum inhibition of replication was observed with lipocortin 1 at 0.5 Ag/ml (14 nM), which gave -77% inhibition, approximately equivalent to the inhibition produced by 0.5 ,M dexamethasone.
Effect of the Anti-Lipocortin 1 Neutralizing Monoclonal Antibody on Dexamethasone-Induced Cell Growth Arrest. The dexamethasone-induced inhibition of A549 cell growth is substantially reversed by the lipocortin 1 neutralizing monoclonal antibody 1A. Fig. 4 Inset shows the result of an experiment (one of four) in which addition of the antibody to the culture medium at 5 Ag/ml almost completely reversed the inhibition of cell proliferation induced by 2 nM dexamethasone while having no effect on its own. To be fully effective, it was necessary for the antibody to be replenished every day. The addition of the nonneutralizing anti-lipocortin 1 monoclonal antibody 1B had no effect at all at this concentration (data not shown).
Production of PGE2 by A549 Cells. To assess the production of PGE2 by A549 cells, cells were cultured in T-150 flasks for 4 days to allow accumulation of easily measurable (10-15 ng/ml; 28-42 pmol) amounts of PGE2 in the culture medium during the growth period. This release is suppressed by treatment of the cells with dexamethasone in a dosedependent fashion with half-maximal inhibition at -1 nM (Fig. 5) . The dexamethasone-induced suppression of PGE2 release is very rapid with a significant (P < 0.001) effect occurring within 30 min of addition of the steroid and persisting throughout the ensuing days of culture even when the steroid is subsequently removed. In the presence of the neutralizing monoclonal antibody 1A (5 pug/ml), the inhibition of PGE2 by 1 nM dexamethasone was reduced from 77.0 ± 0.1% to 46.2 ± 9.6% (P < 0.001; n = 1 experiment).
To test PGE2, the eicosanoid was added to wells containing cells in fresh (i.e., containing no eicosanoids) medium. PGE2 had a biphasic action on cell growth with a mild (-25%, P < 0.01) stimulation observed at 0.01-1 pM but with inhibition of cell proliferation observed at higher concentrations (Fig. 6) .
To determine whether PGE2 could reverse the actions of dexamethasone or indomethacin, the eicosanoid was added to cultures in which growth had been inhibited by the addition of 1 nM dexamethasone or 1 uM indomethacin. Fig. 6 (29, 31) , rat macrophages and thymus in vivo (32, 33) , and human bronchoalveolar lavage fluid (34) . Some undifferentiated cells in culture do not respond to glucocorticoids with an induction of lipocortin 1 (35) , but induction can occur once the cells are differentiated (36) . Other work points to the importance of culture conditions in studying synthesis of lipocortin 1 by cultured cells. Schlaepfer and Haigler (27) observed that there was a peak of lipocortin 1 synthesis by cells immediately after plating or after replenishing the medium with fresh serum. This latter effect could be duplicated by the addition of growth factors such as epidermal growth factor. This clearly implies that factors other than glucocorticoids can regulate the synthesis of lipocortin 1 in cells and also suggests that if the cells are already maximally expressing the protein, it is very difficult to observe any further effect of the glucocorticoids, a fact that may account for much contradictory data in the literature.
In our experiments, we have sought to reduce the interference from other factors by taking the following precautions. (i) The cells were maintained in logarithmic-phase growth and were not allowed to reach confluence as this diminishes their responsiveness to corticosteroids (unpublished observations). (ii) We have used charcoal-stripped FCS in the culture medium so that endogenous steroids and possibly other low molecular weight cofactors in the serum that might influence lipocortin 1 synthesis are removed. (iii) We have incubated our cells for several days in steroid-free medium prior to the addition of glucocorticoids to allow the surge in lipocortin 1 synthesis that occurs after the plating procedure to subside, thus allowing a more facile determination of the freshly synthesized protein.
Steroids can produce a dual effect promoting (i) the translocation of lipocortin 1 to the extracellular domain and then (ii) an increased synthesis taking place over a longer time span (37) . Although lipocortin 1 has no signal sequence, there are several reports suggesting that the protein can be recovered from the pericellular domain of cells and in some cases is present in quite high concentrations in secretory fluids such as prostatic secretion (38) . Browning etal. (29) , in their study on human monocyte synthesis of lipocortin that used radioactive methionine-labeling techniques, clearly observed the presence of a labeled protein on the external cell surface. This has also been seen in other studies using an ELISA and other detection techniques (31) . Because lipocortin 1 can produce biological actions when added directly to cells, or given systemically to animals, and because of the existence of a lipocortin binding protein on the surface of several cell types (39), we have speculated that this pericellular pool is biologically important. Therefore, in analyzing the effect of glucocorticoids on lipocortin 1 synthesis, we have paid special attention to this pool and indeed find that it increases after glucocorticoid treatment. These subtle changes in lipocortin 1 disposition are certain to be missed if the total cellular lipocortin is simply assayed after lysis of the cells in detergent-containing buffers and this may explain some contradictory data in the literature.
A further indication that cell surface lipocortin 1 is the biologically important pool in A549 cells comes from our experiments with the neutralizing monoclonal antibody lA. This is a well-characterized monoclonal antibody and has Proc. Nad. Acad Sci. USA 89 (1992) -I r been reported (21) to reverse some actions ofglucocorticoids. In our hands monoclonal antibody 1A, but not the nonneutralizing monoclonal antibody 1B, at 5 Ag/ml was able virtually to reverse the inhibitory activity produced by an EC50 concentration of dexamethasone. There are now several reports (16, 20, 21 ) that antibodies to lipocortin 1 can interfere with the effects of antiinflammatory steroids and it is difficult to explain these data other than on the basis that there is an extracellular or pericellular pool of lipocortin that is biologically active and that this pool is altered by glucocorticoid steroids.
The mechanisms whereby dexamethasone and lipocortin 1 produce an arrest of cell growth are not entirely clear. Our results suggest that these agents interfere with the production of an eicosanoid, which is important in regulating cell proliferation. Many workers have suggested that eicosanoids can modulate cell growth although the actual nature of these metabolites and the direction of the regulation seem to vary from model to model. For example, some authors suggest that lipoxygenase products are important mediators of cell proliferation (e.g., ref. 40 ) whereas eicosanoids such as PGE2 have generally been shown to be growth inhibitory (e.g., ref. 41) .
Our data clearly show that A549 cells constitutively release large amounts of PGE2 into the culture medium. Glucocorticoids are well-known to suppress PGE2 release and an early experiment with indomethacin showing that this too had growth inhibitory effects led us to believe that it was the PGs rather than the lipoxygenase products that were active. Our dose-response studies with PGE2 indicate that the effects of PGE2 on cell growth are biphasic with a moderate stimulation occurring at low doses and growth suppression occurring at concentrations >0.1 nM. Although we were able to reverse drug-induced inhibition of proliferation with PGE2, we were never able totally to restore proliferation to its control level. This observation could indicate that there are other factors (possibly other eicosanoids) that are also important in controlling proliferation in this system.
It is interesting to note that the time course for inhibition of PGE2 production by dexamethasone corresponded very closely to that of the induction of lipocortin 1, that the addition of the recombinant lipocortin 1 protein also leads to a total inhibition in PGE2 in this system, and that the neutralizing monoclonal antibody provided some protection from the dexamethasone effect. This provides strong evidence for a causal link between the two events.
In summary these experiments show that glucocorticoids have a dramatic effect on the growth of the A549 human adenocarcinoma cell line in culture and point to one mechanism whereby this may occur; namely, the induction of cell surface lipocortin 1 followed by a fall in eicosanoid production, possibly PGE2, leads to changes in cell growth. No doubt there are many mechanisms whereby such complex agents as steroids can regulate cell replication (42) and it will be interesting to see whether this mechanism is common to many other cell types or is unique to the A549 adenocarcinoma cell line.
